PSP Research LLC Makes New Investment in NewAmsterdam Pharma Company N.V. $NAMS

PSP Research LLC purchased a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,920 shares of the company’s stock, valued at approximately $523,000.

Several other large investors have also made changes to their positions in the company. Atle Fund Management AB lifted its stake in shares of NewAmsterdam Pharma by 1.8% during the fourth quarter. Atle Fund Management AB now owns 197,036 shares of the company’s stock valued at $6,912,000 after acquiring an additional 3,411 shares during the period. Handelsbanken Fonder AB lifted its position in NewAmsterdam Pharma by 2.5% during the 4th quarter. Handelsbanken Fonder AB now owns 415,800 shares of the company’s stock valued at $14,586,000 after purchasing an additional 10,000 shares during the period. DNB Asset Management AS acquired a new position in NewAmsterdam Pharma during the 4th quarter valued at about $706,000. Navalign LLC acquired a new position in NewAmsterdam Pharma during the 4th quarter valued at about $46,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in NewAmsterdam Pharma during the 4th quarter valued at about $253,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the sale, the chief executive officer directly owned 174,144 shares in the company, valued at $5,790,288. This represents a 71.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis G. Lange sold 44,619 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the sale, the director owned 10,360 shares of the company’s stock, valued at $315,151.20. This trade represents a 81.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,168,286 shares of company stock worth $38,211,967 over the last ninety days. 12.74% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

NAMS has been the topic of a number of research reports. Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Guggenheim upped their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Truist Financial initiated coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $48.00.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $33.72 on Wednesday. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.78 and a 1 year high of $42.21. The business has a 50-day moving average of $32.49 and a two-hundred day moving average of $34.28. The company has a market capitalization of $3.94 billion, a P/E ratio of -18.84 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. On average, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.